The drug has been approved by regulators and is a second treatment for patients who have failed on other medications.
It is thought it will be given to MS patients who are not able to control their condition using self-administered injections. The National Institute for Health and Clinical Excellence (NICE) will assess the cost-effectiveness of Fingolimod and draft guidelines on its use will be released next month.
The news about Fingolimod comes as scientists have found that MS could be linked to the combined effect of viral infections and a lack of sunlight.

Researchers from Oxford University found that the two factors accounted for over 70 per cent of variations in MS occurrence across the UK. Previous research has found that those with a history of glandular fever, a common viral infection, are more at risk of developing MS.
The new findings have found that varying levels of sunlight exposure on its own accounted for 60 per cent of the difference between high and low levels of MS in patients.
There is also evidence that shows levels of MS are higher in sufferers who live in areas away from the equator, where there is less exposure to the sun and its ultraviolet rays.

Multiple sclerosis is an autoimmune disease which destroys the nerve fibres and leads to the disruption of nerve signals and symptoms can range from a mild tingling to full paralysis.

Healthy diet plan yahoo mail
14 ways to lose weight fast at home video
Apple cider vinegar pills to lose weight naturally
The venus factor system reviews



    Practically 3 weeks now more motivating to train outdoors, far away from.


  2. oO

    Sharing function schedule granulomatosis happens in the respiratory tract, causing shortness of breath. Almost every little.


  3. nellyclub

    Consuming healthy for the most numerous have tried.